key: cord-1017562-d99uth32
authors: Alhusain, Faisal; Alromaih, Azam; Alhajress, Ghassan; Alsaghyir, Abdullah; Alqobaisi, Ali; Alaboodi, Talal; Alsalamah, Majid
title: Predictors and Clinical Outcomes of Silent Hypoxia in COVID-19 Patients, a Single-Center Retrospective Cohort Study
date: 2021-09-16
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.09.007
sha: 3920597f17b8777d3a5a99712d2523b7b81f5934
doc_id: 1017562
cord_uid: d99uth32

BACKGROUND: Patients with COVID-19 usually present with fever and respiratory symptoms such as cough, sputum production, and dyspnea. However, they may suffer from severe hypoxemia without a clinical correlation with the respiratory symptoms, also known as silent or apathetic hypoxia. The aim of the study was to assess the predictors and clinical outcomes of COVID-19 patients without dyspnea. METHODS: A single-center retrospective cohort study, based on data extracted from the electronic hospital information system, with COVID-19 patients over a 10-month period in Riyadh, Saudi Arabia. RESULTS: Of the COVID-19 patients presenting at the Emergency Department with a SpO2 < 90%, 13% had silent hypoxia. The majority of the patients required BiPAP, 34% were intubated and 60% were admitted to an intensive care unit. There was no association between dyspnea and gender, age group, body mass index, or comorbidity. Cough, fever, and chronic cardiac diseases were predictive for dyspnea in a regression analysis. There was no difference in the clinical outcome between patients with silent dyspnea or dyspnea. Age and obesity were significantly associated with a decrease in survival, and an increase in the initial SpO2 increased survival. CONCLUSION: Patients with cardiac disease are more likely to present with silent hypoxia. The SpO2 saturation in COVID-19 may be an independent predictor of survival. Silent hypoxia in COVID-19 patients does not appear to have an association with increase in mortality.

April 2020 described a COVID-19 case of a man in his sixties who initially developed fever and cough. The patient was deeply cyanotic but not agitated or in distress, although the oxygen saturation was 66%, and the respiratory rate 36 per minute. 7 In May of 2020, another case report was published about a 72-year-old obese male with a history of diabetes and hypertension, who presented at the Emergency Department (ED) with minimal respiratory symptoms but a low oxygen saturation. 8 Within a few days, the patient's condition worsened and he died. 8 In 2020, the University of Chicago Stritch School of Medicine, US reported three patients with hypoxia with minimal respiratory symptoms. All denied any difficulty in breathing, and was comfortable without any apparent respiratory distress. 9 In September 2020, an Indian case report described a 56-year-old male smoker with diabetes, presenting with low-grade fever, dry cough, fatigue, and loss of appetite, but he denied having dyspnea although the oxygen saturation was 78% on room air. 10 In addition, a 2020 US study concluded that home pulse oximetry, telemonitoring, and earlier institution of oxygen supplementation for hypoxemic COVID-19 outpatients could be beneficial. 11 However, since the novel virus is not fully understood, the current study aimed to assess the predictors and clinical outcomes of COVID-19 patients without dyspnea.

This was a single-center retrospective cohort study based on data extracted from an electronic hospital information system (BESTCare) of patients presenting at a tertiary academic medical center in Riyadh, Saudi Arabia. The hospital has a bed capacity of 1501 with more than 100 J o u r n a l P r e -p r o o f emergency beds. All patients who present at the ED are triaged by the emergency staff, depending on the condition and vital signs which are manually entered in the BESTCare system.

The study included all pediatric and adult patients admitted from March 24, 2020 to December 31, 2020 through the ED with an initial pulse oximeter reading, oxygen saturation (SpO2), < 90% at room air and a positive COVID-19 polymerase chain reaction (PCR) test. The study excluded patients with a missing initial SpO2 at room air (2 patients). The data included demographic information (age, gender, body mass index (BMI), and initial vital signs), symptoms, comorbidities, initial blood gas, and the clinical management. proportion, and the comparison between dyspnea and silent hypoxia cases was done with a Chisquare test. The prevalence was calculated with a 95% confidence interval (CI). A model was run for a binary logistic regression including cough, fever, nausea, vomiting, diarrhea, sore throat, comorbidities, and medication. The model was run twice to assess the predictors for presenting with silent hypoxia and the predictors for mortality. The 95% CI and odds ratio (OR) were reported. All tests were considered significant with a p-value less than 0.05.

This study included all the patients presenting at the ED with a SpO2 < 90% from March 24, 2020 to December 31, 2020. Of 195 patients, 133 (68%) were male. The highest proportion J o u r n a l P r e -p r o o f (n=163, 84%) of the sample were in the 45 years and above age group. For the BMI, more than two thirds of the sample (n=162, 83%) were in the overweight or obese categories. The most frequent triage symptoms were dyspnea (n=170, 87%), cough (n=155, 77%) and fever (n=133, 68%). The physician identified symptoms were almost similar to the triage symptoms, with dyspnea (n=154, 79%), cough (n=133, 68%) and fever (n=136, 70%). Almost half had hypertension (n=102, 52%) and diabetes (n=97, 50%).

Regarding the management, the highest proportion of the sample required either bi-level positive airway pressure (BiPAP) (n=56, 29%) or intubation (n=66, 34%). More than half of the sample required admission to an intensive care unit (ICU) (n=116, 60%). Of the ICU group, only 18 (16%) were admitted for less than 4 days. Heparin (n=175, 90%), Azithromycin (n=50, 26%), and Steroids (n=110, 56%) were the most frequently administered treatment. In terms of survival, 74% (n=144), survived. The baseline characteristics for the sample is listed in Table 1 .

According to Table 2 , the majority of the sample (68%, n=115) with dyspnea were male, and in the group with no dyspnea, 72% (n=18) were male. Age and BMI were not statistically significant between the two groups. The group with silent hypoxia had significantly less cough (40%) and fever (40%) compared to the group with dyspnea (cough 82% and fever 72%), (p=<0.01 and 0.001). Hypertension, diabetes, dyslipidemia, cancer, chronic respiratory disease, chronic kidney disease, obesity and bronchial asthma were not significant between the two groups. Chronic cardiac disease were more prevalent (n=8, 32%) in the silent hypoxia group compared to 14% (n=23) in the dyspnea group (p=0.018). Intubation and ICU admission were higher in the dyspnea group (37% n=63, 64% n=107, respectively) than the silent hypoxia group (12% n=3, 36% n=9, respectively), (p-value=0.013 for intubation and 0.007 for ICU admission).

There was no relationship between dyspnea and gender, age group, body mass index, or comorbidity. Cough, fever, and chronic heart diseases were predictive for dyspnea in a regression analysis (Table 3 ). There was a significant association between cough and dyspnea (OR 6.26; 95% CI 2.47-15.9). Fever was also strongly associated with dyspnea (OR 3.63; 95% CI 1.43-9.26). In addition, patients with a chronic heart disease were more likely to experience silent dyspnea than patients with chronic kidney disease (OR 0.36; 95% CI 0.12-1.02).

The current study indicated no association between survival and gender, triage symptoms, or comorbidities. However, age was significantly associated with a decrease in survival (OR 0.94; 95% CI 0.92-0.97), and similarly, patients with a high BMI were strongly associated with a decrease in survival (OR 0.95; 95% CI 0.92-0.99). An increase in the initial SpO2 was associated with increased survival (OR 1.05; 95% CI 1.03-1.02). Interestingly, there was no difference in the clinical outcome in the groups with silent dyspnea and dyspnea. The regression for the predictors of survival is summarized in Table 4 .

In all countries affected by COVID-19 in early 2020, EDs and ICUs admitted mostly COVID-19

patients. There was a global increase in the reported infection rate and mortality. 3, 12, 13 However, literature reported many patients with COVID-19 presenting with silent hypoxia. [14] [15] [16] It is important to know the risk factors and the causes contributing to the presentation of silent hypoxia in COVID-19 patients. The purpose of this study was to identify the factors and the outcomes in COVID-19 patients presenting at a tertiary academic hospital with an initial SpO2 < 90.

One of the distinctive features of patients diagnosed with COVID-19 is the presence or absence of dyspnea ("silent" or "happy" hypoxia), in relation to their level of oxygen saturation. 17 Experiencing dyspnea is a subjective feeling reported by the patient. 18 According to the American Thoracic Society "dyspnea per se can only be perceived by the person experiencing it". 19 25 In the current study, the prevalence of silent hypoxia was 13%, which is lower than reported in literature.

In the current study, most of the group (68%) with dyspnea were male. A similar study conducted in France reported the prevalence of dyspnea in males as 42.5%, 23 and in the Indian study, 58.2% of the male patients were hypoxic. 24 In Milan, the prevalence of silent hypoxemia in females was 63.2%, which is inconsistent with the current study indicating that the majority of the silent hypoxia group (72%) were male. Most of the group (72%) with silent hypoxia in this study were older than 54 years, in contrast to a study by Brouqui et al. reporting that 57.3% of the silent hypoxia patients were less than 55 years. 23 However, a European study reported the mean age for the patients with silent hypoxemia as 67.8. 17 In the current study, 55% of the group with dyspnea were obese (BMI of 30 kg/m 2 and above), higher than the 5.2% reported in Italy. 17 The rate of admission to ICU for silent and dyspneic hypoxemic patients was 36% vs 64% J o u r n a l P r e -p r o o f in the current study compared to 26.5% vs. 38.6% reported in Italy. 17 In France, only 5.1% of the silent hypoxia cases was admitted to ICU. 23 In the current study, 37% of the dyspneic group were intubated, compared to a study reporting that 8% of COVID-19 patients with dyspnea were intubated. 24 In the Brouqui et al. study regarding the effect of chronic cardiac disease on silent hypoxia in COVID-19 patients, reported an increased risk in chronic cardiac disease patients, similar to the current study. 23 However, the Brouqui et al. study found that chronic respiratory disease increased the risk of silent hypoxia, not supported by the current study.

COVID-19 patients may present with a decreased oxygen saturation due to the ongoing respiratory tract infection, with the body attempting to compensate for the decreased oxygen level through several physiological mechanisms. An important consideration is whether the oxygen saturation at the initial presentation has a prognostic value or not. The current study indicated that a decrease in the oxygen saturation in the initial presentation is associated with a poorer outcome which is consistant with a study by Dillon et al. suggested that the pre-hospital lowest recorded oxygen saturation may be a predictor of mortality in COVID -19 patients. 26 Similarly, a study from the United Kingdom reported that the oxygen saturation at room air as a strong predictor for patient outcome and mortality 27 , also supported by a Peruvian study reporting that an oxygen saturation lower than 90% on admission was an important predictor of in-hospital mortality in patients with COVID-19. 28 Another study concluded that a low level of oxygen on admission was strongly associated with more critical illness and mortality. 20 Locally in Saudi Arabia, on 2 March 2020, the first case of the COVID-19 pandemic was confirmed by the Ministry of Health, followed by a restriction on international travel the next day. By the 21 st of May, a lockdown was mandated with other measures to control the J o u r n a l P r e -p r o o f pandemic. Although the government took early precautionary measures by enforcing the restriction of movement and travel, the number of daily cases gradually increased. On June 16, the number of new daily cases peaked at 4919 positive cases. However, due to the early intervention and availability of medical equipment, including oxygen and ventilators, the mortality rate was of the lowest compared to other countries. By the beginning of July, the curve in Saudi Arabia reached the peak with a total number of confirmed cases exceeding 100000. 29 The majority of the cases of silent hypoxia in the study occurred during the peak. The absence of dyspnea in the initial assessment of a COVID-19 patient should be not be interpreted as a mild case. The current study and other studies recommend a SpO2 pulse oximetry for all patients with symptoms of COVID-19 to detect silent hypoxia cases.

The current study is the first local study to identify the predictors of silent hypoxia in COVID-19 patients and the clinical outcomes. However, the study was a retrospective study, done in a single academic tertiary center, rather than multiple centers. Another limitation is that not all potential cofactors were available in the electronic system.

The results suggest that cardiac disease patients are more likely to present with silent hypoxia.

The SpO2 saturation in COVID-19 patient may be an independent predictor of survival.

However, silent hypoxia in COVID-19 patients was not associated with increase in mortality. The current study investigated an aspect of silent hypoxia and highlights the need for accurate international and national databases to adequately assess and predict silent hypoxia in COVID-19 patients.

J o u r n a l P r e -p r o o f No funding sources.

None declared.

Ethical approval for the study was obtained from the Institutional Review Board, King Abdullah International Medical Research Center, National Guard-Health Affairs, Riyadh, Saudi Arabia, protocol number RC20.624.R.

J o u r n a l P r e -p r o o f 

SARS-CoV-2) | Johns Hopkins ABX Guide

The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century

COVID-19) events as they happen

COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data

COVID-19: Transmission, prevention, and potential therapeutic opportunities

Extra-respiratory manifestations of COVID-19

Covid-19 med stille hypoksemi. Tidsskr den Nor Laegeforening 2020

Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19

Why COVID-19 silent hypoxemia is baffling to physicians

Silent hypoxia: a frequently overlooked clinical entity in patients with COVID-19

Considerations for target oxygen saturation in COVID-19 patients: Are we under-shooting?

Editorial: Coronavirus disease 2019 (COVID-19) -advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges

COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far

Silent Hypoxemia of COVID-19 Pneumonia: Typical Courses With Implications for Outpatient Care

Caution against precaution: A case report on silent hypoxia in COVID-19

Possible silent hypoxemia in a COVID-19 patient: A case report

Prevalence and outcome of silent hypoxemia in COVID-19

An official American thoracic society statement: Update on the mechanisms, assessment, and management of dyspnea

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Asymptomatic hypoxia in COVID-19 is associated with poor outcome

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia

Association Between Hypoxemia and Mortality in Patients With COVID-19

Pre-hospital lowest recorded oxygen saturation independently predicts death in patients with COVID-19

Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: An observational cohort study

Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima

Publications Highlights.pdf (accessed 23 May2021)

J o u r n a l P r e -p r o o f Tables: J o u r n a l P r e -p r o o f